Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use.
Cocaine use is associated with increased cardiovascular mortality and can promote acute coronary syndrome (ACS). Use of beta-blockers is controversial in patients who use cocaine, and the safety and efficacy of these medications in ACS in patients actively using cocaine is unknown. We enrolled 90 patients with ACS and positive urine drug screen for cocaine. Patients received standard ACS therapy plus either labetalol (n = 60) or diltiazem (n = 30). Blood pressure and heart rate were measured at baseline and 48 hours. Levels of serum CD40 ligand, interleukin (IL)-6, and choline at baseline and 48 hours were determined. There were no baseline differences in hemodynamics or serum levels of inflammatory markers between the labetalol and diltiazem groups. Both groups experienced a significant and equivalent decrease in BP and HR at 48 hours compared with baseline. At 48 hours of treatment, there were significant decreases of 17% in CD40 ligand (P < .005) and 16% in IL-6 (P < .005) but no change in choline in the diltiazem group. Furthermore, in the labetalol group, there were significant differences of 30% in CD40 ligand (P < .005 time and group comparison), 22% in IL-6 (P < .005 time and group comparison), and 18% in choline (P < .005 time and group comparison). There were no adverse events during hospitalization in any patients who received labetalol. In conclusion, labetalol appears to be safe in cocaine-associated ACS. Furthermore, labetalol provides a beneficial hemodynamic response and, in comparison to diltiazem, potentiates an anti-inflammatory vascular response in this setting.
Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA.
Michael H
MH
Hoskins
Rebecca M
RM
Leleiko
Julie J
JJ
Ramos
Srikanth
S
Sola
Patrick M
PM
Caneer
Bobby V
BV
Khan
D054058:Acute Coronary Syndrome / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology* / Q000592:standards; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D023201:CD40 Ligand / Q000097:blood; D002317:Cardiovascular Agents / Q000494:pharmacology*; D019970:Cocaine-Related Disorders / Q000150:complications*; D004110:Diltiazem / Q000494:pharmacology*; D005260:Female; D005845:Georgia; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007741:Labetalol / Q000494:pharmacology* / Q000592:standards; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D015415:Biomarkers; D002317:Cardiovascular Agents; D015850:Interleukin-6; D023201:CD40 Ligand; D004110:Diltiazem; D007741:Labetalol